This week, we have conversations with Peter Nolan, CEO of BlackFinBio, and Kim Kraemer, CEO and founder of Waterhouse Brands.

Interview times:

01:57 BlackFinBio

19:36 Waterhouse Brands

BlackFinBio

BlackfinBio is a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases.

Its pipeline comprises BFB-101, a clinical stage AP4B1 replacement adeno-associated virus (AAV) gene therapy for spastic paraplegia 47 – an ultra-rare genetic neurological disease for which no treatment currently exists.

BFB-201 is a preclinical stage gene therapy to treat several rare dopamine deficiency disorders.

The U.S. Food and Drug Administration (FD ...